SCHEMBL16625459

SCHEMBL16625459

COC(=O)CC[C@@H](C)[C@H]1CCC2C3CC[C@@H]4C[C@@H](NCCO)CC[C@]4(C)C3CC[C@@]21C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 4/20 0.73
▸ HIF1A Q16665 3/20 0.73
▸ VDR P11473 3/20 0.73
▸ CYP2C9 P11712 2/20 0.73
▸ USP2 O75604 4/20 0.58
▸ MAPT P10636 3/20 0.58
▸ MAPK1 P28482 3/20 0.58
▸ LMNA P02545 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ CASP7 P55210 3/20 0.57
▸ TP53 P04637 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ BLM P54132 2/20 0.57
▸ TDP1 Q9NUW8 2/20 0.57
▸ CYP3A4 P08684 2/20 0.57
▸ MDM4 O15151 1/20 0.57
▸ HSPD1 P10809 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ PTPN2 P17706 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18844016 1.00 GPBAR1 (0.73) GPBAR1HIF1AVDRCYP2C9USP2
SCHEMBL18844059 1.00 GPBAR1 (0.73) GPBAR1HIF1AVDRCYP2C9USP2
SCHEMBL16625460 1.00 GPBAR1 (0.73) GPBAR1HIF1AVDRCYP2C9USP2
SCHEMBL21510926 1.00 GPBAR1 (0.73) GPBAR1HIF1AVDRCYP2C9USP2
SCHEMBL21024324 1.00 GPBAR1 (0.73) GPBAR1HIF1AVDRCYP2C9USP2
SCHEMBL21510975 1.00 GPBAR1 (0.73) GPBAR1HIF1AVDRCYP2C9USP2
SCHEMBL21024362 1.00 GPBAR1 (0.73) GPBAR1HIF1AVDRCYP2C9USP2
SCHEMBL21024376 1.00 GPBAR1 (0.73) GPBAR1HIF1AVDRCYP2C9USP2
SCHEMBL21024290 1.00 GPBAR1 (0.73) GPBAR1HIF1AVDRCYP2C9USP2
SCHEMBL21511047 0.92 GPBAR1 (0.72) GPBAR1HIF1AVDRCYP2C9USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203088-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease DEPYMED INC. (US) 2023-06-29 — — US disclosed
US-20230203088-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease DEPYMED INC. (US) 2023-06-29 — — US disclosed
US-20200270300-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease OHR PHARMACEUTICAL, INC. (US) 2020-08-27 — — US disclosed
US-10556923-B2 Aminosteroids for the treatment of a PTP1B associated disease OHR PHARMACEUTICAL INC. (US) 2020-02-11 — — US disclosed
US-20190202858-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease OHR PHARMACEUTICAL, INC. (US) 2019-07-04 — — US disclosed
US-20170129914-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease OHR PHARMACEUTICAL, INC. (US) 2017-05-11 — — US disclosed
US-20170129914-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease OHR PHARMACEUTICAL, INC. (US) 2017-05-11 — — US disclosed
US-9546194-B2 Aminosteroids for the treatment of a PTP1B associated disease OHR PHARMACEUTICAL, INC. (US) 2017-01-17 — — US disclosed
US-9546194-B2 Aminosteroids for the treatment of a PTP1B associated disease OHR PHARMACEUTICAL, INC. (US) 2017-01-17 — — US disclosed
US-20150099727-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease OHR PHARMACEUTICAL INC. (US) 2015-04-09 — — US disclosed
US-20150099727-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease OHR PHARMACEUTICAL INC. (US) 2015-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099727-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease HSD17B13, PPME1, CYP27A1 GPBAR1 565/4885HIF1A 4125/4885VDR 1439/4885
US-10556923-B2 Aminosteroids for the treatment of a PTP1B associated disease HSD17B13, PPME1, CYP27A1 GPBAR1 565/4885HIF1A 4125/4885VDR 1439/4885
US-20200270300-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease HSD17B13, PPME1, CYP27A1 GPBAR1 565/4885HIF1A 4125/4885VDR 1439/4885
US-20230203088-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease HSD17B13, PPME1, CYP27A1 GPBAR1 565/4885HIF1A 4125/4885VDR 1439/4885
US-20190202858-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease HSD17B13, PPME1, CYP27A1 GPBAR1 565/4885HIF1A 4125/4885VDR 1439/4885
US-20170129914-A1 Aminosteroids for the Treatment of a PTP1B Associated Disease HSD17B13, PPME1, CYP27A1 GPBAR1 565/4885HIF1A 4125/4885VDR 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback